Saturday 17 October 2026
Export TMO’s income statement to Excel — free account
Thermo Fisher Scientific Inc.
TMO Healthcare Diagnostics & Research
Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024. In the quarter to June 2026, revenue grew 10.5%, EPS grew 9.35%, free cash flow grew 51.8% and total debt rose 18.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
690.00
6.49
−0.93%
Follow TMO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
26.93 | 26.98 | 32.61 | 27.97 |
+8 more quarters Free account |
P/S ratio |
4.01 | 4.05 | 4.90 | 4.19 | |
P/FCF ratio |
25.27 | 26.93 | 34.47 | 29.84 | |
P/Operating CF |
87.53 | 153.40 | 63.19 | 81.88 | |
P/B ratio |
3.53 | 3.52 | 4.09 | 3.59 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.77 | 4.86 | 5.48 | 4.84 | |
EV/EBITDA |
19.94 | 20.52 | 23.20 | 20.54 | |
EV/Operating CF |
24.53 | 26.51 | 31.24 | 27.66 | |
EV/FCF |
30.04 | 32.36 | 38.54 | 34.44 | |
Quick Ratio |
0.90 | 0.85 | 1.25 | 0.84 | |
Current Ratio |
1.55 | 1.53 | 1.89 | 1.50 | |
Net Debt/EBITDA |
12.09 | 14.16 | 8.63 | 10.88 | |
Debt/Assets |
34.62% | 35.37% | 32.49% | 30.92% | |
Debt/Equity |
0.74 | 0.77 | 0.67 | 0.62 | |
Asset Turnover |
0.43 | 0.43 | 0.43 | 0.43 | |
Operating CF/Net income |
1.22 | 0.72 | 1.76 | 1.39 | |
Capex/Depreciation |
(0.55) | (0.50) | (0.60) | (0.61) | |
Interest Coverage |
5.20 | 5.27 | 6.18 | 5.59 | |
Research and Development Expense of Revenue |
3.03% | 3.05% | 2.92% | 3.11% | |
Selling, General and Administrative Expense of Revenue |
19.45% | 19.82% | 19.26% | 19.44% | |
Intangible Assets out of Total Assets |
0.65 | 0.66 | 0.59 | 0.64 | |
Share Based Compensation of Revenue |
0.68% | 0.75% | 0.69% | 0.63% | |
Graham Net Nets |
(0.20) | (0.21) | (0.13) | (0.16) | |
Graham Number |
243.92 | 239.25 | 238.01 | 229.49 | |
Earnings Yield |
3.71% | 3.71% | 3.07% | 3.58% | |
Free Cash Flow Yield |
3.96% | 3.71% | 2.90% | 3.35% | |
Revenue per Share |
32.33 | 29.58 | 32.40 | 29.42 | |
Operating CF per Share |
5.73 | 3.20 | 9.17 | 5.92 | |
Capex per Share |
(1.20) | (0.99) | (1.16) | (1.06) | |
Free Cash Flow per Share |
4.53 | 2.22 | 8.01 | 4.87 | |
Cash per Share |
10.95 | 8.75 | 26.80 | 9.38 | |
Shareholders Equity per Share |
142.01 | 139.62 | 141.68 | 134.98 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
142.01 | 139.62 | 141.68 | 134.98 | |
Free Cash Flow |
1,679.00 | 825.00 | 3,019.00 | 1,839.00 | |
Working Capital |
8,296.00 | 7,695.00 | 13,518.00 | 7,407.00 | |
Capital Expenditures |
(446.00) | (367.00) | (438.00) | (400.00) | |
Net Current Asset Value |
(37,123.00) | (39,025.00) | (28,221.00) | (29,701.00) | |
EV/EBIT |
27.14 | 27.83 | 31.52 | 28.19 | |
Capex to Sales |
0.04 | 0.03 | 0.04 | 0.04 | |
Price to Operating Income |
22.83 | 23.16 | 28.20 | 24.42 | |
| Other line items | |||||
Average Receivables |
9,022.50 | 8,829.50 | 8,545.50 | 8,583.00 | |
Average Payables |
3,124.00 | 3,196.50 | 3,350.50 | 2,863.00 | |
Average Inventory |
5,593.00 | 5,360.00 | 5,201.50 | 5,587.50 | |
Average Assets |
107,202.00 | 106,161.00 | 103,832.00 | 101,692.00 | |
Average Common Equity |
51,581.50 | 50,648.50 | 51,483.00 | 49,998.50 |
Columns are period end dates